Amicus Therapeutics Inc [FOLD] stock is trading at $14.21, up 0.21%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The FOLD shares have gain 30.61% over the last week, with a monthly amount glided 50.37%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Amicus Therapeutics Inc [NASDAQ: FOLD] stock has seen the most recent analyst activity on December 22, 2025, when TD Cowen downgraded its rating to a Hold but kept the price target unchanged to $14.50 for it. Previously, Citigroup started tracking the stock with Buy rating on December 17, 2025, and set its price target to $17. On September 18, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $14 on the stock. Morgan Stanley upgraded its rating to a Overweight but stick to its price target of $108 on July 17, 2025. Morgan Stanley downgraded its rating to a Equal-Weight and reduced its price target to $12 on December 13, 2024. Jefferies started tracking with a Buy rating for this stock on September 06, 2024, and assigned it a price target of $18. In a note dated May 30, 2024, Wells Fargo initiated an Overweight rating and provided a target price of $18 on this stock.
Amicus Therapeutics Inc [FOLD] stock has fluctuated between $5.51 and $14.36 over the past year. Currently, Wall Street analysts expect the stock to reach $14.25 within the next 12 months. Amicus Therapeutics Inc [NASDAQ: FOLD] shares were valued at $14.21 at the most recent close of the market. An investor can expect a potential return of 0.28% based on the average FOLD price forecast.
Analyzing the FOLD fundamentals
Amicus Therapeutics Inc [NASDAQ:FOLD] reported sales of 598.70M for the trailing twelve months, which represents a growth of 19.46%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at 0.05%, Pretax Profit Margin comes in at 0.01%, and Net Profit Margin reading is 0.03%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.1 and Total Capital is 0.05. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.92.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.17 points at the first support level, and at 14.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.25, and for the 2nd resistance point, it is at 14.30.
Ratios To Look Out For
For context, Amicus Therapeutics Inc’s Current Ratio is 2.99. Also, the Quick Ratio is 2.09, while the Cash Ratio stands at 0.96. Considering the valuation of this stock, the price to sales ratio is 7.32, the price to book ratio is 19.02.
Transactions by insiders
Recent insider trading involved DAVID CLARK, Officer, that happened on Dec 19 ’25 when 25642.0 shares were purchased. President and CEO, Campbell Bradley L completed a deal on Dec 15 ’25 to sell 77926.0 shares. Meanwhile, Chief People Officer Clark David Michael sold 25643.0 shares on Dec 15 ’25.
